Inhibrx Biosciences (INBX) Form 4 Inhibrx / Brendan P. Eckelman ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Eckelman Brendan P.

(Last) (First) (Middle)

C/O INHIBRX, INC.

11025 NORTH TORREY PINES ROAD, SUITE 200

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibrx, Inc. [ INBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/03/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/03/2023		S(1)		22,213	D	$23.412(2)	2,133,340	I	By the Eckelman Living Trust dated February 5, 2014(3)
Common Stock	01/03/2023		S(1)		8,598	D	$24.3575(4)	2,124,742	I	By the Eckelman Living Trust dated February 5, 2014(3)
Common Stock	01/03/2023		S(1)		2,084	D	$25.0927(5)	2,122,658	I	By the Eckelman Living Trust dated February 5, 2014(3)
Common Stock	01/04/2023		S(1)		4,102	D	$23.1072(6)	2,118,556	I	By the Eckelman Living Trust dated February 5, 2014(3)
Common Stock	01/04/2023		S(1)		3,003	D	$23.9903(7)	2,115,553	I	By the Eckelman Living Trust dated February 5, 2014(3)
Common Stock								160,000	I	By trust(8)
Common Stock								160,000	I	By trust(9)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$23.3	01/03/2023		A		40,000		(10)	01/03/2033	Common Stock	40,000	$0	40,000	D

1. Name and Address of Reporting Person^*

Eckelman Brendan P.

(Last) (First) (Middle)

C/O INHIBRX, INC.

11025 NORTH TORREY PINES ROAD, SUITE 200

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Eckelman Living Trust Dated February 5, 2014

(Last) (First) (Middle)

C/O INHIBRX, INC.

11025 NORTH TORREY PINES ROAD, SUITE 200

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Eckelman Living Trust dated February 5, 2014.

2. The shares were sold in multiple transactions at prices ranging from $23.01 to $24.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

3. These securities are directly owned by the Eckelman Living Trust dated February 5, 2014. Brendan P. Eckelman is the trustee of the Eckelman Living Trust dated February 5, 2014 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Eckelman Living Trust dated February 5, 2014.

4. The shares were sold in multiple transactions at prices ranging from $24.01 to $24.99, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

5. The shares were sold in multiple transactions at prices ranging from $25.02 to $25.48, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

6. The shares were sold in multiple transactions at prices ranging from $22.60 to $23.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

7. The shares were sold in multiple transactions at prices ranging from $23.61 to $24.41, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

8. These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor son. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.

9. These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor daughter. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.

10. Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments forthirty-six (36) months thereafter.

Remarks:

	/s/ Kelly D. Deck, attorney-in-fact	01/04/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.